Akebia Therapeutics, Inc.

NasdaqCM:AKBA Stock Report

Market Cap: US$399.3m

Akebia Therapeutics Management

Management criteria checks 3/4

Akebia Therapeutics' CEO is John Butler, appointed in Sep 2013, has a tenure of 11.25 years. total yearly compensation is $2.78M, comprised of 28.7% salary and 71.3% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $2.69M. The average tenure of the management team and the board of directors is 1.9 years and 6 years respectively.

Key information

John Butler

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage28.7%
CEO tenure11.3yrs
CEO ownership0.7%
Management average tenure1.9yrs
Board average tenure6yrs

Recent management updates

Recent updates

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Aug 02
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23
Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10
Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

CEO Compensation Analysis

How has John Butler's remuneration changed compared to Akebia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$43m

Dec 31 2023US$3mUS$796k

-US$52m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$3mUS$765k

-US$94m

Sep 30 2022n/an/a

-US$158m

Jun 30 2022n/an/a

-US$163m

Mar 31 2022n/an/a

-US$276m

Dec 31 2021US$3mUS$718k

-US$282m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$300m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$6mUS$696k

-US$385m

Sep 30 2020n/an/a

-US$391m

Jun 30 2020n/an/a

-US$386m

Mar 31 2020n/an/a

-US$268m

Dec 31 2019US$4mUS$648k

-US$280m

Sep 30 2019n/an/a

-US$245m

Jun 30 2019n/an/a

-US$217m

Mar 31 2019n/an/a

-US$193m

Dec 31 2018US$3mUS$595k

-US$144m

Sep 30 2018n/an/a

-US$68m

Jun 30 2018n/an/a

-US$65m

Mar 31 2018n/an/a

-US$53m

Dec 31 2017US$3mUS$543k

-US$74m

Compensation vs Market: John's total compensation ($USD2.78M) is about average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Butler (60 yo)

11.3yrs

Tenure

US$2,775,123

Compensation

Mr. John P. Butler, MBA, serves as Non-Executive Director at Wren Therapeutics Limited since 2023. He has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013 an...

Leadership Team

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director11.3yrsUS$2.78m0.67%
$ 2.7m
Steven Burke
Senior VP of Research & Development and Chief Medical Officer5.3yrsUS$1.21m0.16%
$ 627.4k
Erik Ostrowski
Senior VPless than a yearno datano data
Richard Malabre
Chief Accounting Officerless than a yearno datano data
Kimberly Garko
Senior VP & Chief Technical Officerless than a yearno datano data
Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration1.9yrsno datano data
Mercedes Carrasco
Senior Director of Investor & Corporate Communicationsno datano datano data
Carolyn Rucci
Senior VP of Legal2.9yrsno datano data
Meredith Bowman
Senior VP & Chief People Officer2.9yrsno datano data
Nicholas Grund
Senior VP & Chief Commercial Officerless than a yearno datano data

1.9yrs

Average Tenure

60yo

Average Age

Experienced Management: AKBA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director11.4yrsUS$2.78m0.67%
$ 2.7m
Michael Rogers
Independent Director6yrsUS$145.79k0.044%
$ 175.7k
Adrian Adams
Independent Chairperson6yrsUS$171.63k0.062%
$ 246.7k
LeAnne Zumwalt
Independent Director3.8yrsUS$143.31k0.020%
$ 80.0k
Ronald Frieson
Independent Director3.1yrsUS$147.97k0.020%
$ 80.0k
Steven Gilman
Independent Director6yrsUS$139.87k0.040%
$ 159.4k
Cynthia Smith
Independent Director6.3yrsUS$151.50k0.044%
$ 174.3k
Myles Wolf
Independent Director4.7yrsUS$144.43k0.031%
$ 123.9k

6.0yrs

Average Tenure

64.5yo

Average Age

Experienced Board: AKBA's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akebia Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth